← FDA DRUG APPROVALS

FDA ANDA · ANDA205069

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Sponsor: XIROMED

APPLICATION
ANDA205069
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-22
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOLPrescription
ETHINYL ESTRADIOL 0.02MG,0.03MG,0.035MG, NORETHINDRONE ACETATE 1MG,1MG,1MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 3 · standardAP
2022-03-18Labeling · Supplement 2 · standardAP
2018-06-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →